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A literature review
ROBBERT HUIJSMAN •
Financial problems of governments and the consequent urge to set limits on health care growth have increased the
importance of economic rationalization. A systematic review of the present body of knowledge might facilitate the
need to set priorities in health care policies and research in an ageing society with growing numbers of the elderly
and chronically ill. After explaining the purpose and methods of full economic evaluation, we review the literature
on 3 major chronic diseases, diabetes mellitus (20 publications), rheumatoid arthritis (15) and chronic obstructive
pulmonary disease (COPD) and asthma (8). This review serves 2 objectives: to review the existing literature and to
assess its quality. The review reveals a lack of full economic evaluation in this sector of health care. The total number of
references to the specified chronic diseases covers 5% of all economic literature and 44% of all references under Index
Medicus' heading 'economies', while the burden of illness is substantial, resulting in high indirect costs to the patients
themselves and to society. The dominant approach is cost-effectiveness analysis (71%), followed by cost-benefit
analysis (20%). Cost-utility analysis is rare (9%), partly because it is still in the phase of development. However, this
approach can deal better with the objectives of many interventions in chronic care, i.e. increasing the quality rather
than the quantity of life. We make a plea for full economic evaluation of chronic care programmes and for the
development of quality of life measures which cover the broad domain of well-being of the chronically ill.
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with ageing populations and the strong relation be-
tween prevalences of chronic diseases and age, there will
be increasing numbers of people with chronic diseases, of
which many depend on the provision of health care. In
this article, we adhere to the viewpoint that in ageing
societies the burden of illness which comes with chronic
diseases is a relevant starting point for establishing prior-
ities for health care programmes and economic evaluation
(besides the traditional focus on interventions), thus
adopting the measurement iterative model of Tugwell et
al. from quantifying the burden of illness, through aeti-
ology to validating interventions and their evaluation.
Others have addressed the demographic and
epidemiological trends, which we need to discuss briefly
in order to substantiate our viewpoint and to gain more
insight into the effects of an ageing society. At first glance,
there seems to be little information from the literature
that could be used to support policy choices based on
economic (other than, for instance, societal or ethical)
considerations of the costs and outcomes of alternative
health care programmes in the complex area of care for
the chronically ill. Figures of the use of care resources are
difficult to provide and there have been few attempts to
analyse economically programmes particularly targeted at
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the elderly and chronically ill. Therefore, after explaining
the purposes and methods of full economic evaluation, we
review the literature on full economic evaluation of care
for the chronically ill. This review serves 2 objectives: to
review the existing literature and to assess its quality.
SELECTION OF EMPIRICAL FIELD: 3 CHRONIC DISEASES
Practical limitations made us carefully select 3 major
chronic diseases, serving as a kind of case study for the
total field of chronic diseases. We selected diabetes mel-
litus (DM), rheumatoid arthritis (RA), and chronic ob-
structive pulmonary disease (COPD) and asthma. These
chronic diseases have been chosen for several reasons: a)
in The Netherlands they rank among the top 10 diseases
and causes of death in the general population2, b) they
cause a severe burden of illness for both the individual
patient and society and c) their prevalence rates are
highly related to age (table I), which is of great import-
ance to an ageing society.
SOME RELEVANT TRENDS AND THEIR IMPACT ON
THE CARE SECTOR
With variation between countries, the demographic trend
is unmistakeably towards a larger population of the (very)
old. In Western Europe, the number of elderly above 65
years is higher in Denmark, Belgium, Eastern Germany
and the UK (almost 16%) than in The Netherlands
(13%).-' A similar picture can be seen for the percentage
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of 85 years and over. Double-ageing, i.e. an increasing
share of die very old widiin the population of elderly, is
concentrated in females. Predictions on the future situ-
ation in die Dutch population show an increasing share
of die elderly in die total population, to up to 24% by die
year 2040.4 Simple extrapolation for die year 2000, com-
bining demographic trends widi age-specific care con-
sumption rates have shown tiiat The Netherlands will
experience a yearly increase in patients of approximately
2%.5'6 By the turn of die century, total expenditure will
increase by 20-25% in real terms. The share of the elderly
widiin die client populations of health care services,
which in The Netherlands was on average already 40%
in 1990, will rise further.''
Such extrapolations are unsatisfactory for a number of
reasons. First, one may expect age-specific demands to
shift over time. Subsequent cohorts do not just get older,
but their health status also improves over time, due to
changing healdi habits and attitudes and more effective
prevention and curative programmes. This may lead to a
concentration of illness in die last years of life, but it may
also cause longer periods of illness, albeit at later stages in
life. Many doubt whedier die age-specific prevalences of
a number of important chronic diseases (table I) will
change significantly in the coming years. Nevertheless,
when age-specific prevalences remain more or less stable,
die double-ageing of die population and the strong rela-
tion between prevalences and age, will inevitably result
in increasing numbers of chronically ill.
It is not only the prevalence but also the intensity of
healdi care consumption which increases with age. Thus,
die average cost per year per person is substantially higher
in older dian in younger age groups (table 2).' For women
in the highest age brackets the figures are even 30%
higher. Mental disorders are die most expensive disease
category, accounting for 20% of all health care costs and
30% of all traceable diagnosis-related costs. For the elderly
of 80 years and over the average cost related to dementia
accounts for 18% of all costs. The costs related to demen-
tia will double towards die year 2030. Also, die costs of
some of tile chronic diseases which we focus on in diis
article belong to the group of diseases widi die sharpest
increases in costs during die decades to come. Setting the
Table 1 Prevalence of some chronic diseases in The Netherlands (per
(M: male, F: female), 1990
Table 2 Average costs per capita for chronic diseases in
The Netherlands, 1988 (in Dfl)
Age (years)
0-19 20-44 45-64 65-79 £80 Total
7 37 124 163 31
6 32 134 248 30
COPDand
asthma 13
Diabetes mellitus 3
Rheumatoid
arthritis 1 2 14 46 87 11
Mental disorders 210 615 550 847 3297 592
Other diseases 677 830 1,325 3,519 7,865 1,350
Non-traceable 428 534 790 1,290 2,194 679
Diabetes mellitus
Rheumatoid arthritis
COPD
Asthma
Source: reference 2
M
F
M
F
M
F
M
F
0-14
0.69
0.61
0.59
0.00
4.15
0.90
30.03
16.84
15-24
1.73
2.01
0.59
0.56
2.56
7.01
21.68
20.05
Age
25-44
5.19
5.67
1.40
4.64
8.90
6.59
10.70
15.59
(years)
• 45-64
25.89
26.36
7.93
9.15
46.41
19.80
5.05
11.12
65-74
55.82
69.96
11.50
20.80
129.41
35.29
4.50
6.44
275
59.44
83.41
13.27
32.18
219.05
52.21
0.00
5.51
Total
13.50
19.23
3.60
7.40
30.70
13.94
14.13
14.11
Total costs per
capita 1,332 1,994 2,748 5,960 13,854 2,693
Source: reference 7
cost level of 1988 at 100, die index of average health care
costs in The Netherlands will be 139 in 2030. The indices
for rheuma and diabetes mellitus will rise to above 17O.7
Anotiier departure from die simple extrapolation arises
from the fact that technology in the area of service deliv-
ery for die elderly and chronically ill may also progress.
There is considerable scope for the introduction of (new)
technologies which may help people to stay independent
and postpone die use of institutional care.8 However,
taking technological development in die 'cure' sector as
an example, it is not self-evident that technological
change will make die production of services less expensive
because it is often aimed at increasing the effectiveness of
interventions rather dian saving costs.
ECONOMIC APPRAISAL
Relevance
The trends we described above, result in a growing gap
between the demand for services and die resources avail-
able from die public budget to finance these demands.
One of die options to bridge diis gap is to increase the
efficiency of public spending and healdi care policy, in
which economic appraisal is playing an increasing role.
Some countries, such as Australia and Canada, already
use economic appraisal as an integrated part of their
decisions on die reimbursement of new pharmaceutical
products. In most developed
1,000 inhabitants), by gender countries major decisions on,
for instance, die initiation of
screening programmes are
not taken without consid-
eration of dieir cost-effect-
iveness profiles. These initi-
atives concentrate on the
cure sector; policy decisions
widiin die care sector seem
to lack an economic founda-
tion. Until now, die costs of
most services have not been
evaluated and die outcomes
of most care provisions have
not been measured.9 There-
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Are both inputs and outputs of the alternatives examined?
No Yes
Examines only the outputs Examines only inputs/costs Examines both inputs and outputs
Comparison of
tl alternatives?
1A
No Outcome description
3A
Yes Efficiency or efficacy evaluation
Partial evaluation
Partial evaluation
• l
IB
Cost description
3B
Cost analysis
2
4
Partial evaluation
Cost-outcome description
Full economic evaluation
Cost-minimization, CEA, CBA, CUA
Source: reference 10
Figure Different forms of economic appraisal
fore, a review of die literature on economic analysis of care
for the elderly and chronically ill may be useful.
Different methods
Only those studies which make a simultaneous compar-
ison between alternative strategies and where bodi die
costs and outcomes are being considered, are seen as full
economic evaluations (figure). Drummond et al.10 define
full economic evaluation as "die comparative analysis of
alternative courses of action in bodi dieir costs and con-
sequences". This definition rules out odier forms of re-
search, such as randomized clinical trials or efficacy evalu-
ations (which assess only the outcomes of clinical
strategies) and cost analysis and cost of illness studies
(which exclude die outputs of programmes). These forms
of partial economic evaluation often result in estimated
cost per (treated) patient and can be useful if die effect-
iveness of alternative strategies has been well established
or does not differ between alternatives.
In comparing costs and consequences of alternative pro-
grammes, diere are 4 basic types of full economic evalu-
ation: cost-minimization analysis, cost-effectiveness ana-
lysis, cost-benefit analysis and cost-utility analysis.10
Cost-minimization is a comparative approach to identify
die least expensive provision from a set of alternatives
widi die same outcome. Results are often reported in
terms of cost per treated patient, aldiough diis is a measure
of output radier dian outcome. Often, delicate and sub-
jective judgement is necessary to discriminate cost ana-
lyses from cost-minimization. Therefore, we decided to
exclude this type of analysis from our review.
Cost-effectiveness analysis (CEA) is a method in which
costs and consequences of some provisions are compared
with dieir best alternatives. Costs are valued in money,
while effects are measured in some natural unity. The unit
of effect depends on the programmes that are being com-
pared and may take the form of a cost per life saved or per
saved life year or levels of function or proportion of
patients in whom symptoms are controlled. Since die
ultimate aim of healdi care programmes is to prevent
morbidity and mortality, years of life gained are typically
used as die unit of effect.1' In cost-benefit analysis (CBA),
all costs and benefits, including die gains in healdi, are
valued in monetary terms and the results are usually
reported as a net cost or benefit. Although some audiors
argue diat CBA can also be applied to one single strategy,
we rule that out as it is not a full economic evaluation
according to Drummond et al.'s definition.10 Cost-utility
analysis (CUA) can be seen as an extension of cost-effect-
iveness analysis in die sense drat changes in the quality
of life are taken into account. The result of a CUA is
usually a cost per quality adjusted life year (QALY)
gained. QALYs combine quantity and quality of life into
one single index which allows comparisons across pro-
grammes. Although diis type of analysis has the advantage
of combining effects diat programmes can have on differ-
ent outcomes by valuing the change in each outcome, die
analyst is faced with, many problems, such as weighing
different dimensions into one index1 and valuing human
life and suffering.11 The result is an ongoing debate12 and
die development of alternative measures for CUA, for
instance 'healthy years equivalent'.1^'1'* As die measure-
ment of diese concepts have been pursued in very differ-
ent ways, it seems too early to recommend stand-
ardization.15
Methodology of full economic evaluation: a check list
Because full economic evaluation is a radier extensive
form of research, a check list is helpful. We used die check
list of Drummond et al., containing 10 questions to be
considered when assessing die appropriateness of die
mediodology employed in a study (table 3).10'15
The first question, concerning die alternatives being
compared and die viewpoint(s) underlying die compar-
ison, is very general and relevant to all scientific efforts.10
A comprehensive description of die competing altern-
atives (question 2) and substantiated evidence of die
effectiveness of diese options (question 3) enables die
reader to judge die usefulness, applicability and compar-
ability of die programmes and to assess die completeness
of die study. Sometimes, analysts eidier explicidy or im-
plicitly choose the current programme as an alternative
('doing nodiing') to die new strategy, but we feel that diis
choice should be substantiated in detail. The perspective
of die study has to be clearly idendfied because of the
consequences for die selection of relevant costs and out-
comes (question 4). Most authors recommend die societal
perspective in which all direct and indirect costs, widiin
and outside die healdi care sector, are included.1 •
Sometimes, a narrower perspective can be adopted, for
instance, die viewpoint of a diird-party payer, a care
provider or the consumer. Each of diese alternatives is
more limited dian die societal perspective and die con-
sequent resource allocations may be suboptimal from the
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societal point of view. However, this is the very nature of
decentralized decision making. All relevant costs and
outcomes of all relevant alternatives have to be included
in the analysis (question 5) and valued sensibly (question
6). This often raises problems, because the real costs are
sometimes unknown. Economists are reluctant to use
tariffs or charges in economic evaluation, because these
are negotiated over between healdi care providers and
third-party payers and usually do not represent real costs.
In practice it can be very difficult and costly to reveal the
actual costs, so we adopt a pragmatic approach in this
matter. The stream of costs and outcomes have to be
discounted over time (question 7), because different pro-
grammes generally have different time profiles of costs
and/or consequences, but must be compared at one point
in time (usually the present). In this way we eliminate the
consequences of time preference, i.e. the phenomenon
that individuals and society prefer money or resources
now instead of later because of the benefits in the interim,
even in a world without inflation and bank rates.10 The
social rate of time preference is a measure of society's
willingness to forgo consumption (gratification) today in
order to have a greater consumption (gratification) to-
morrow. Although there remains some debate, die most
commonly used rate at present is 5% per year.15 In the
early 1980s, this choice lacked serious empirical back-
ing, but a study of short- and long-term interest rates in
9 countries came up with supportive evidence to fix the
discount rate at 5%.18 Another point of discussion con-
cerns the discounting of heakh effects,19 for which some
authors advocate lower interest rates,20 but there seems to
be no solid ground to justify a specific regimen of time
preference.18
Another important foundation of economic evaluation is
the concept of marginal analysis (question 8). In order to
make the proper allocation decisions for scarce resources,
it is necessary to examine additional or marginal effects of
additional or marginal increases in resource expenditure.
Table 3 A check list for assessing economic evaluations in health
care
1 Was a well-defined question posed in an answerable form?
2 Was a comprehensive description of the competing
alternatives given?
3 Was there evidence that the programme's effectiveness had
been established? How strong was the evidence (through a
randomized, contolled clinical trial)?
4 Were all important and relevant costs and consequences for
each alternative identified?
5 Were costs and consequences measured accurately in
appropriate physical units?
6 Were costs and consequences valued credibly?
7 Were costs and consequences adjusted for differential timing?
(discounting)
8 Was an incremental analysis of die costs and consequences
of alternatives performed?
9 Was a sensitivity analysis performed?
10 Did presentation and discussion include all of the issues that
are of concern to users?
Source: reference 15
Sensitivity analysis should also show the influence of
various discount rates on die results of the study (question
9). In general, sensitivity analysis is used to assess die
robustness of die assumptions underlying the study and of
die qualitative conclusions and to identify areas for fur-
ther research on diose variables which are crucial to die
results. The last question of die check list is crystal clear,
but quite often researchers 'forget' to address, for instance,
die distributional, legal and ediical issues relevant to die
(introduction of die) programme. Finally, die analyst
should be as explicit as possible about the various meth-
odological, technical and value judgements he or she has
made carrying out die study.10
REVIEW OF THE LITERATURE
Selection methods
We used MEDLINE (1984-1993) on CD-ROM to find
publications on die 3 chronic diseases. Search procedures
in CD-ROM make use of die medical subject headings of
die Index Medicus, which are based on bodi die title and
die contents of a publication. We selected all references,
including full economic evaluations, on diabetes mellitus
(widi 8 medical subject headings: diabetes mellitus, keto-
acidosis, angiopadiies, coma, diet, nephropadiies, neuro-
padiies and retinopadiy), rheumatoid arthritis (widi 3
headings: arthritis-rheumatoid, osteoardiritis and osteo-
myelitis) and chronic obstructive pulmonary diseases, in-
cluding asdima (widi 'lung-disease-obstructive' as the head-
ing). This sample of publications was completed, using die
Economic Evaluation Bibliography of approximately
1,900 publications, ranging from journal articles and edi-
torials to discussion and research papers.21 According to
die audiors, this bibliography covers almost 100% of die
English language references over die period 1964—1992.
For OOPD and asdima, diis article is also based on a
recent review.22 Drummond et al.'s definition10 was used
to classify an economic study as a full economic evalu-
ation. Finally, to judge die rigour of an economic evalu-
ation, we used die check list, as explained above.
General results
Table 4 presents the stream of publications for die 3
chronic diseases during die period 1984-1993. The aver-
age number of publications varies from 2,100 to 2,780
papers per year, of which 0.3% fits die Index Medicus'
subject heading 'economies'. Although diis heading is
broad, it provides us widi adequate access to die full
economic evaluation literature.
The bibliography contains 1,887 publications of which
56% are not on full economic evaluations: 18% have been
classified as cost analysis studies (including cost of illness
studies), 21% as review articles and methodological pa-
pers and 17% as other papers, including comments and
letters to the editor(s). For all diseases togedier, CEA is
the most commonly used method (31%), followed by
CBA (10%) and CUA (3%). The latter is a new but
rapidly growing area of work, although the quality of
technical execution is still poor and die concept of utility
itself is debated upon, as mentioned above.15'23
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One-fifth of all economic studies are concerned with
diseases of the circulatory system and 13% focused on
infectious and parasitic diseases. Mental disorders have
been studied in 5% of all publications. The bulk, however,
is classified into the category of odiers, also including the
3 chronic diseases central to this paper. The most import-
ant type of interventions described are drugs (22%), ther-
apy (26%) and prevention (17%). Alternatives in health
service organization or location of care have been studied
less frequently (13%).21
These general figures raise the suspicion that chronic care
is lacking attention from economists. Table 5 further
demonstrates this caveat. In total, the references to die 3
chronic diseases cover only 5% of all economic literature.
Relatively more attention has been paid to cost(-minim-
ization) analysis, particularly cost of illness studies, but we
did not classify these as full economic studies. Full eco-
nomic evaluation studies into chronic diseases and the
elderly have been performed as often as in other health
care fields, accounting for approximately 45% of all refer-
ences in the economic literature. Other economic, espe-
cially cost of illness, studies may serve to clarify the
economic significance of disease-specific intervention. If
any publication has been used in diat way, it will be stated
clearly.
Table 4 Number of publications for the 3 selected chronic
diseases, 1984—1993. All economic references, including full
economic evaluation are in parentheses
Year of COPD and Diabetes Rheumatoid
publication asthma mellitus arthritis
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
2,448
2,557
2,783
2,672
2,704
2,887
3,006
2,785
1,905
(6)
(3)
(5)
(5)
(9)
(9)
(4)
(9)
(4)
2,527 (10)
1,954 (3)
2,181 (-)
2,267 (-)
2,368
2,559
2,581
2,803
2,906 (13)
1,864 (9)
1,545 (20)
(2)
(3)
(7)
(8)
2,627 (10)
2,752 (8)
2,912 (10)
2,920 (2)
3,063
3,031
3,060
2,938
1,969
2,552
(9)
(7)
(8)
(4)
(2)
(7)
Total number 26,274 (64) 23,028 (65) 27,824 (67)
Source: Medline
Table 5 Full economic evaluation references for selected chronic
diseases
COPD and
Type of study asthma a
Diabetes Rheumatoid All studies
mellitus arthritis (%)
CEA
CBA
CUA
Total number
Of which in
Backhouse21
15
4
1
20
12
11
3
1
15
14
580 (70)
191 (23)
56 (7)
827 (100)
Methodological rigour
The last line of table 5 shows that die completeness of die
bibliography is (almost) perfect for rheumatoid arthritis
and diabetes mellitus, but far less satisfying for COPD and
asdima. Our review research resulted in 8 more studies
than found by Backhouse et al.21 We used die same
sources, so to us die reason remains unclear, odier dian
our special interest in this topic. Some references (author
names) in die bibliography were spelt incorrectly.
Table 6 summarizes our efforts to address the mediodo-
logical rigourness of die full economic evaluations. In
each field of chronic diseases a small number of articles
could not be assessed in diis way, because diey have been
published as abstracts only. The methodological quality
varies gready, although in most cases diere is a good
research question and evidence of die effectiveness of a
particular programme. The relevant alternatives and die
identification of all costs and outcomes are not always
spelt out in much detail. Greater caveats are observed
widi respect to discounting, incremental analysis (diough
this is irrelevant when a study is based on a randomized
trial) and sensitivity analysis. The accuracy by which costs
have been measured and valued is often unclear and not
explained in sufficient detail. Overall, studies into die 3
diseases do not differ from each odier when assessed
against Drummond et al.'s check list. •
THE ECONOMIC LITERATURE ON SELECTED CHRONIC
DISEASES
Diabetes meUitus
The estimates for the prevalence of diabetes mellitus
(DM) vary from 1 to 2%,24 '25but approximately 50% of
die non-insulin-dependent diabetes mellitus (NIDDM)
remains undiagnosed.26>27The most common complica-
tions associated widi DM are impaired vision, cardiovas-
Table 6 The rigourousness of selected full economic evaluations: a
summary report
Drummond et al.'s
checklist
COPD and
asthma °
n-20
Diabetes
mellitus
n-15
Rheumatoid
arthritis
n-8
a Adjusted on the basis of Rutten-Van Molken et al.
No evaluation possible 4 2 2
Number of articles with
Good research question 13 12 4
Description of
alternatives 12 9 5
Evidence of
effectiveness 8 11 4
All costs/outcomes
identified 7 9 5
Costs/outcomes
measured well 11 10 5
Costs/outcomes valued
credibly 5 5 5
Discounting 2 6 1
Incremental analysis 4 1 3
Sensitivity analysis 2 5 2
Presentation complete 11 9 4
a Adjusted on die basis of Rutren-Van Molken et al.
b Officially published as an abstract only
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cular diseases, gangrene and amputation. The numerous
side-effects incur heavy medical costs. Diabetic retino-
pathy affects approximately half of the people with dia-
betes, causing substantial societal costs of blindness in
terms of lost production.28 Nevertheless, most studies
focused on the direct costs only, with a few studies on the
cost of illness aspects of DM.29"51 The health cost of
diabetes is estimated to account for 4—5% of all health
care expenditures. Other social i.e. indirect costs, due to
lost production and premature death, account for 40-50%
of total cost of illness.29
Until now, there have been a few intervention studies
focusing on the effectiveness of dier or medication."
Table 7 shows that most economic appraisal has been
dedicated to screening,3''"38 sometimes combined with
treatment,39"^2 and to educational activities.43""45 The
other articles cover diet, insulin therapy, and a pro-
gramme with different locations of care.
With 11 references, CEA is the most frequently performed
type of study. CBA has been performed 3 times35>38'41and
CUA only once.46 Three references40"42 originated from
the same research group, all using the same population-
based simulation model.
Screening and treatment of diabetic retinopathy received
a good deal of attention, accounting for 60% of all refer-
ences and has been proven to be cost-effective from a
societal and governmental perspective. From the view-
point of a third-party payer, however, some additional
incentives might be necessary. Screening for the early
detection of diabetic retinopathy is a very cost-effective
strategy, even if only 60% of the insulin-dependent pa-
tients are being covered. Each person receiving compre-
hensive eye examinations and appropriate treatment at
the earliest signs of disease represents a savings of nearly
10.000 USS.40'41
For cases of retinopathy detected early, laser surgery can
prevent further damage to the eye, with a success rate of
nearly 90%. Unfortunately, it is not easy to detect diabetic
retinopathy, because no noticeable loss of vision appears
until the damage is well advanced.
In The Netherlands, a recent full economic evaluation of
ophthalmic care, including ophthalmoscopy and photo-
coagulation, demonstrated clear net benefits of screen-
ing for IDDM patients but failed to provide sufficient
(economic) arguments to justify special ophthalmic care
for N1DDM patients. But these findings depend on the
assumptions about the age of onset of diabetic retinopathy
and the actual moment of diagnosing this event: the
younger the age of onset, the more favourable the cost-ef-
fectiveness ratios. Screening for NIDDM did prove to be
cost-effective, although less so than for IDDM because the
threat of blindness is less severe. Annual eye examina-
tions using dilation of the pupils has proven to be the most
effective screening strategy, both in the USA39 and in
Sweden,40 even for relatively low rates of compliance.
Health education programmes have been studied more
frequently than suggested by table 6, accounting for almost
20% of all references in the economic literature, but full
economic evaluation studies have been reported only 3
times. Less popular are diet and nutrition (although
good for the single cost-utility study, focusing on a diet
plus exercise programme for NIDDM),46 and out-patient
activities.47 Antibiotics against osteomyelitis, which is
part of the natural progression of diabetes in the lower
extremities, is not effective, but early amputation of the
toe in combination with antibiotics has proven to be
cost-effective.49
In general, many behavioural and education programmes
for diabetes seem to be cost-beneficial, ^although there
is little really strong evidence and some questions remain
Table 7 Economic appraisal of diabetes mellitus: main characteristics of the studies, by intervention (n=15)
Characteristics of patient/study population(s)
Diagnosis N Groups a RandomFirst author, year and [ref.no] Type of study Type of intervention
Drummond
Foulds
Lairson
Sculpher
Waugh
Dasbach
Fendrick
Javitt
Javitt
Kacerovslcy-Bielesz
Weerdt
Chen
Kaplan
Mengutu
Scheffler
1992
1983
1992
1991
1986
1991
1992
1989
1991
1984
1991
1991
1988
1991
1992
[34]
[35]
136]
[37]
[38]
[39]
[40]
[41]
[42]
[43]c
[44]
[45]c
[46]
147]
[48]
CEA
CBA
CEA
CEA
CEA
CEAb
CBAb
CEAb
CEAb
CBA
CEA
CEA
CUA
CEA
CEA
Screening
Screening
Screening
Screening
Screening
Screening and treatment
Screening and treatment
Screening and treatment
Screening and treatment
Education
Education
Education and monitoring
Diet, exercise
Insulin therapy
Total programme
Retinopathy
Retinopathy
Retinopathy
Retinopathy
Retinopathy
Retinopathy
Retinopathy
Retinopathy
Retinopathy
1DDM/N1DDM
IDDM
NIDDM
NIDDM
IDDM/NIDDM
Pregnancy DM
-
-
352
3318
-
-
750
31,000
17,245
300
558
89
76
104
189
2
2
4
3
2
3
-
-
-
2
2
2
2
2
2
Yes
No
No
No
No
No
No
No
No
?
Yes
Yes
Yes
Yes
Yes
a Number of groups
b Computer simulation based on secondary data analyses
c Officially published as an abstract only
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to be solved, such as the long-term effects and the effect-
iveness of application in a more representative patient
population instead of self-selected patients. Education
programmes tend to focus on nutrition and exercise,
because in Western societies 60-90% of NIDDM patients
are obese.51 In fact, NIDDM is rarely observed in coun-
tries where food supplies are limited.52 The American
Diabetes Association therefore suggested that pharma-
cological management of NIDDM should not begin until
a serious programme of diet and exercise has failed to
produce improved glucose tolerance. New advances in
treatment, such as new insulins, new monitoring methods
at home and pumps to replace syringes may improve
patients' quality of life and reduce costs, but have yet to
be evaluated.28
Rheumatoid arthritis
Rheumatoid arthritis affects the quality of life of patients
over a very long period of progressing disease with periodic
flare-ups and remissions. In The Netherlands, nearly 8%
of all elderly above 65 years suffer from arthritis, either in
the feet and hands or of other kinds; more strictly, 2-3%
suffer RA (table I). Using MEDLINE we found almost
28,000 references to RA during the period 1984-1993 of
which 6.7% had been dedicated to evaluation. However,
we found only 8 full economic studies (5 CEA's, 1 CBA
and 2 CUA; table 8). From a societal perspective, this lack
of research is not very justifiable, because of the fact that
the burden of RA to patients and society is quite large.
All musculoskeletal diseases together account for 5-9%
of all direct medical expenses. This is probably an un-
derestimation, because direct and out-of-pocket expenses
for medication are not registered properly by disease cat-
egory and yet are very important for RA. Additionally,
the indirect costs account for 50 to even 85% of all costs,54
so patients with RA are incurring substantial indirect
monetary costs, especially earnings losses,55'56 and intan-
gible costs of pain, disability and consequent depression
in addition to significant direct costs.54"57
Three studies focused on medication, 2 for patients with
rheumatoid arthritis58159 and 1 for patients widi
osteoarthritis.60 Thompson et al.58 evaluated the cost-ef-
fectiveness of auranofin (an oral gold preparation) in a
randomized trial of RA patients with a placebo control
group and found significant, albeit slight, improvements
in 4 out of 6 clinical outcome parameters and 1 negative
side-effect (diarrhoea). However, medical costs (includ-
ing paid help) and indirect costs (travelling time of pa-
tients and work disability) were higher for the experimen-
tal group. Kvien et al.60 concluded that a variable dosing
regimen of naproxen for patients with knee and hip
arthritis is superior to a fixed regimen, resulting in a lower
drug consumption (by 20-30%), similar levels of efficacy
and possibly better tolerance.
Two other studies focused on different surgical strategies
for total joint arthroplasty61 and advanced degenerative
knee arthritis.62 In the latter study, which used a model
simulating 25 years of experience from primary surgery at
age 40 years and included a sensitivity analysis, total knee
arthroplasty dominated 3 other surgical strategies, such as
unicompartmental resurfing and tibial osteotomy. Al-
though total joint arthroplasty in itself is radier expensive,
other direct costs of medical and long-term care are much
lower.61"64 However, further evidence based on random-
ized trials with different strategies is necessary.
The sixth study is a very early full economic evaluation
(1969), addressing a wide range of RA treatments at a
rheumatic centre (a 48 bed hospital) in Glasgow. The
present value of benefits exceeded total costs under all
assumptions explored in the sensitivity analysis, but the
treatment at the centre was not compared to any other
alternative (implicitly 'doing nothing').
The last 2 studies compared 2 different locations of care
for patients with rheumatoid arthritis, i.e. in-patient care
with intensive out-patient therapy.66'67 In the latter
study, hospitalization improved by a factor of 3 but costs
were a factor of 2.5 higher. Thus, although this study
found slightly better outcomes at substantially higher
costs, society might be reluctant to invest in the new
alternative, because of concern for the national healtli
care budget, although such a strategy would clearly im-
prove the quality of life of patients.54'58'61 Other re-
searchers, although not undertaking a full economic
evaluation, did not find any possibilities of achieving
significant reductions of hospitalization rates for RA pa-
tients.68-69
Table 8 Economic appraisal of rheumatoid arthritis: main characteristics of the studies, by intervention (n-8)
First author
Thompson
Edelson
Kvien
Liang
Maclntyre
Brooks
Pettingill
Helewa
, year and [ref.no]
1988
1990
1991
1986
1991
1969
1980
1989
[58]
[59]
[60]
[61]
162]c
[65]
[66]c
[67]
Type of study
CEA
CEA
CEA
CUA
CUAb
CBA
CEA
CEA
Type of intervention
Medication
Medication
Medication
Total joint arthroplasty
Surgical strategies
Rheumatic centre
Location of care
Location of care
0 Number of groups
b Computer simulation based on secondary data analyses
c Officially published as an abstract only
Characteristics of patient/study population(s)
Diagnosis
Rheumatoid arthritis
Rheumatoid arthritis
O5teoarthritis
Osteoarthritis
Knee arthritis
Rheumatoid diseases
Rheumatoid arthritis
Rheumatoid arthritis
N
293
-
356
-
45
115
119
Groups"
2
2
2
4
2
3
2
71 (women) 2
Random
Yes
Yes
Yes
No
No
No
No
Yes
Economic evaluation of chronic diseases
The results from this pan of the review are not promising,
but are slightly misleading as long as they do not take into
account the non-economic aspects of chronic diseases,
such as the quality of life of RA patients, who are willing
to pay quite a large part of their income for treatment of
their disease.70
Chronic obstructive pulmonary diseases and asthma
COPD is generally used as a broad term for chronic
bronchitis, emphysema, and chronic air-flow limitation.
In English language literature, asthma is distinguished
from COPD, following international consensus. In The
Netherlands, the combined prevalence rates of the 2
conditions (encompassed in the acronym Cara) vary from
10-20% for men (especially elderly men suffer from
COPD) and 5-10% for women or children who especially
suffer from asthma (table I). Approximately 4% of all
health care costs are caused by COPD and asthma. The
associated burden of illness is considerable and will in-
crease further because of ageing.71 Continuous search
during recent years resulted in 20 full economic studies
published over the years 1980-1991. Earlier, Rutten-Van
Mdlken et al. reported on this subject. With some
additional references, table 9 has been adapted from that
source.
Most of these studies related to asthma are concerned with
health educational programmes, either for children,72"74
adults75"77 or both.78 These types of interventions are
relatively inexpensive and in children even seem to result
in actual savings. Compliance has often been proven to
increase.77 Conclusions about home care as a substitute
for institutional care for COPD are not decisive: some
indicate no cost reductions,79'80 while others conclude in
favour of home care.81-82 In highly selected patient popu-
lations, home care seems to be cost-effective, especially if
the communication and coordination between commun-
ity care and the treating physician is well organized.22
Other popular themes in the literature are oxygen ther-
apy83'84 and breathing support aids.85'86 Chronic obstruct-
ive airways disease is the only COPD disorder studied in
detail, with favourable results for oxygen therapy.87 The
simple metred dose inhaler is a more effective aerosol drug
delivery method than the updraft nebulizer, for both
exacerbated obstructive lung disease, and intubated me-
chanically ventilated patients. 7 Portable oxygen cylin-
ders for patients during exercise have not been proven
cost-effective; the major result is improvement of quality
of life.89
Pharmacotherapy, although currently the most important
therapeutic intervention for asthma and COPD (with
more than 25 different drugs in different delivery forms in
The Netherlands alone), has been evaluated by eco-
nomists only 3 times, twice for COPD91'92 and once for
asthma, with favourable results for cromolyn sodium.93 A
Table 9 Economic appraisal of COPD and asthma: main characteristics of the studies, by intervention (n~20) *
First author, year and [ref.no]
Clark
Fireman
Lewis
Deter
Wilson
Windsor
Shields
Bergner
1986
1981
1984
1986
1987
1990
1985
1988
Campbell-Haggerty 1991
Dranove
Strom
Tiep
Schmidt
Jasper
Gay
Hay
Jubran
Ross
Johnson
Toevs
1985
1990
1987
1983
1987
1991
1991
1991
1988
1983
1984
[72]
[73]
[74]
[75]
[76]
[77]
[78]d
[79]
[81]
[80]
[83]
[84]
[85]
[86]
[87]
[91]
[92] d
[93]
[97] d
[98]
Type of study
CEA
CEA
CEA
CBA
CEA
CEA
CEA
CEA
CEA
CEA
CEA
CEA
CEA
CBA
CEA
CEAC
CEA
CBA
CBA
CUA
Type of intervention
Education (children)
Education (children)
Education (children)
Education (adults)
Education (adults)
Education (adults)
Education (all)
Home care
Home care
Home care
Oxygen delivery
Oxygen delivery
Mechanical ventilation
Aer. branch, delivery'
ACT. branch, delivery'
Medication
(alpha-1 antitrypsin)
Medication
(bronchodilators)
Medication
(chromolyn sodium)
Rehabilitation
Rehabilitation
Characteristics of patient/study population(s)
Diagnosis
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
COPD
COPD, asthma
COPD
COPD
COPD
COPD, others
COPD, asthma
Airways obstruction
COPD
COPD
Asthma
COPD
COPD, asthma
N
310
26
76
22
300
267
387
301
17
436
41
9
137
36
18
-
133
53
194
76
Groups
2
2
2
2
4
2
2
3
1
2
2
-
1
2
2
-
2
2
2
2
Random
Yes
No
Yes
No
Yes
Yes
Yes
Yes
-
No
No
-
-
Yes
Yes
-
Yes
No
No
Yes
a Adapted (with some additional references) from Rutten-Van Mfllken et al.
b Number of groups
c Simulation model based on secondary data analyses
d Officially published as an abstract only
e Aerosol bronchodilator delivery
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Dutch multicentre randomized intervention trial in
asthma and COPD has proven that long-term therapeutic
intervention directed at reducing bronchoconstriction
and airways hyper-responsiveness, adding corticosteroids
to a regimen of beta-2-agonists, is more cost-effective
than treatment with a beta-2-agonist plus an anticholin-
ergic drug; the latter in turn is superior to therapy with a
single bronchodilating agent.90-94'95The same favourable
results hold for children.96
Rehabilitation programmes have been subject to CBA97
and CUA.98 The latter is the only CUA we found in the
economic literature on COPD and asthma. This is re-
markable, because the quality of life as an outcome meas-
ure of interventions is equally or even more important
than quantity of life or other outcome measures.99'100
Behavioural programmes to improve compliance to exer-
cise and rehabilitation have proven to be effective.9^'98
However, the samples used in these studies (table 9) are
too small for firm conclusions. Most studies indicate ttiat
die selection of patients is still difficult, but very import-
ant in determining the cost-effectiveness profile.
DISCUSSION
Discussions on the limits to health care growth, in relation
to the financial problems of governments and partially
triggered by demographic, epidemiological and techno-
logical trends, have raised the question of effectiveness
and efficiency of health care programmes. Although the
importance of efficient allocation of resources is growing,
application of full economic evaluation in health policy
decision making is rare.101 Until now, there is little reli-
able evidence in the fields of care for the chronically ill
and elderly on which policy choices can be based. It is
unclear how the complex demands of these patient groups
can be influenced, what the most cost-effective ways are
to accommodate this demand and which mechanisms are
most instrumental in achieving efficient resource alloca-
tion.102
Our review shows that in chronic diseases full economic
evaluation, which we used here in the strict definition,
i.e. excluding cost (-minimization) analysis, is scarce. We
were able to locate 20 publications on COPD/asthma, 15
on diabetes mellitus and 8 on rheumatoid arthritis. These
studies account for 0.2% of all publications concerning
these diseases during the period 1984-1993.
In chronic diseases, economists generally used CEA (in
more than 70% of the studies), followed by CBA (20%)
and CUA (9%). In rheumatoid arthritis CUA has been
done slightly more often (25%). These conclusions con-
firm the findings in the economic bibliography.
Our review has revealed some caveats in the methodology
of full economic studies of programmes targeted at
COPD/asthma, RA and DM. These results are consistent
with the findings of Drummond et al.'5 and Maynard9 that
the methods of full economic evaluation (especially
CUA) are still in the phase of development,101 so diat
economic studies have seldom satisfied a critical review.
Although most studies (in diis review approximately
85%) do state a clear research question and give substan-
tiated evidence of the effectiveness of a particular inter-
vention (66%), based on a detailed description of altern-
atives (75%), only one-fifth of all studies include dis-
counting of different time profiles of costs and outcomes
or an incremental analysis or a sensitivity analysis. Ap-
proximately one-third of all studies reviewed in this article
could be improved by including a comprehensive descrip-
tion of all relevant alternatives and all relevant costs and
consequences of each alternative, measured and valued
properly (table 6). Care needs to be taken that marginal
costs and benefits are measured relative to their highest-
valued alternative use. An appropriate comparator can or
cannot be 'current practice' or 'doing nothing', but this
decision will produce a particular configuration of mar-
ginal costs and benefits.103
Full economic evaluation in COPD/asthma, RA and DM
has revealed many effective interventions in chronic dis-
eases. Some programmes for early discharge from hospitals
are cost-effective for certain groups of RA patients, al-
though the results in different locations of care are not
decisive and less favourable when the total costs of home
care and informal care are fully included. The same holds
for home care (as an alternative to institutional care) for
DM and COPD/asthma. In highly selected patient popu-
lations, home care seems to be cost-effective but effect
measures are frequently hampered by small samples and
intervening factors. Pharmacotherapy did not get much
attention, aldiough it is often an important therapeutic
intervention, especially in COPD/asthma. All the studies
we found came up widi favourable results. The small
number of studies is probably due to the fact that it is
unethical to withhold effective medication from control
groups; 'doing nothing' is not a realistic alternative.
Screening and treatment of diabetic retinopathy received
a good deal of attention, accounting for 60% of all DM
references and has been proven to be very cost-effective,
especially for IDDM and even for less favourable coverage
and compliance rates. Behavioural and education pro-
grammes, which are of special interest to patients with
asthma or DM, seem to be cost-beneficial, although the
long-term effects and the possibilities of generalizing re-
sults to the population remain questionable. This review
makes it clear that the selection of patients is very import-
ant for the cost-effectiveness profile, but still remains
difficult.
There are many problems and challenges to applying
economic appraisal to chronic diseases. It is difficult to
acquire precise cost data in relation to individuals con-
suming medical and social services, in and outside insti-
tutions, comparing the real costs of alternatives for specific
groups of individuals. Secondly, one has to make arbitrary
decisions to split so-called joint costs when comparing
different service patterns for a group of individuals. Other
problems are related to co-morbidity, heterogenity in
need and demand for care, effects of supply-induced de-
mand by offering new forms of care, the problem of
preference drift (as shown here for COPD) and con-
sequent conceptual problems with the meaning and meas-
urement of quality of life. Costs and financing should be
Economic evaluation of chronic diseases
clearly distinguished; governmental agencies tend to fo-
cus on the latter, thus limiting the perspective of the study
and 'forgetting' that the financial burden of long-term
home care programmes shifts from public to private fund-
ing with consequent cumulative effects for chronic and
elderly patients, who are already in the lower social
classes. The problem of measurement and valuation of
informal care has rarely been tackled effectively until
now, but is very important in chronic and long-term
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In the care sector, objective measurement of outcome is
much more difficult than in the cure sector and sometimes
even impossible. Problematic to the economic evaluation
of alternative location of care strategies is that home care
is a basket of very different activities of different profes-
sionals, resulting in many identification problems (which
intervention causes which effect?). Services in the
chronic care sector are meant to serve many objectives,
which go beyond the single dimension of health status.
These objectives have to be made explicit in order to
develop indicators to fully assess the outputs of an inter-
vention. Standardized generic quality of life instruments
are needed to allow comparisons between various inter-
ventions, ^ but additional disease-specific measures and
questionnaires are necessary1"' and will also increase the
sensitivity to change.'*''
Intermediary outcome measures, like, for instance, referral
patterns or length of stay, may say something about the
process of care, but often do not provide sufficient infor-
mation for an economic appraisal. Most relevant is prob-
ably the subjective measurement of outcome, asking
chronic patients to assess the outcomes of services. More
fundamentally, there is a need to use an integrated utility
concept. Health status, pain, comfort, safety and inde-
pendence are relevant dimensions of a broad concept of
well-being in the chronically ill, as has been illustrated for
rheumatoid arthritis.58 '61 '10 'The concepts underlying the
chronic care go far beyond the statement of Gerard and
Mooney diat "only health gain is being sought from health
care resources".103 The challenge remains to opera-
tionalize these concepts and make them applicable to
economic evaluation of health care programmes for the
chronically ill.
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